Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.35 |
| ▸ | CETP | P11597 | 3/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9108191 | 0.84 | PLA2G7 (0.58) | PLA2G7RAF1BRAFGPR84 | |
| SCHEMBL16623945 | 0.81 | PLA2G7 (0.36) | PLA2G7RAF1BRAFGPR84NR1H2 | |
| SCHEMBL9105640 | 0.80 | PLA2G7 (0.47) | PLA2G7BRAFGPR84 | |
| SCHEMBL9108140 | 0.80 | PLA2G7 (0.51) | PLA2G7GPR84 | |
| SCHEMBL9103354 | 0.78 | PLA2G7 (0.59) | PLA2G7RAF1BRAFGPR84NR1H2 | |
| SCHEMBL9892574 | 0.78 | PLA2G7 (0.44) | PLA2G7GPR84CETPHCAR2PPARG | |
| SCHEMBL9101748 | 0.76 | PLA2G7 (0.57) | PLA2G7RAF1BRAFGPR84 | |
| SCHEMBL9108674 | 0.76 | PLA2G7 (0.41) | PLA2G7BRAFGPR84P2RX3HCAR2 | |
| SCHEMBL9889433 | 0.76 | PLA2G7 (0.59) | PLA2G7RAF1BRAFGPR84 | |
| SCHEMBL9107934 | 0.76 | PLA2G7 (0.42) | PLA2G7GPR84P2RX3HCAR2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | PLA2G7 4/4885RAF1 2923/4885BRAF 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.